Plixda Side Effects
Generic name: adapalene topical
Medically reviewed by Drugs.com. Last updated on May 9, 2024.
Note: This document provides detailed information about Plixda Side Effects associated with adapalene topical. Some dosage forms listed on this page may not apply specifically to the brand name Plixda.
Applies to adapalene topical: topical cream, topical gel/jelly, topical lotion, topical solution, topical swab.
Serious side effects of Plixda
Along with its needed effects, adapalene topical (the active ingredient contained in Plixda) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking adapalene topical:
More common
- burning sensation or stinging of skin
- dryness and peeling of skin
- itching of skin
- redness of skin
Other side effects of Plixda
Some side effects of adapalene topical may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Rare
- worsening of acne
For healthcare professionals
Applies to adapalene topical: topical cream, topical gel, topical lotion, topical solution, topical swab.
Dermatologic
- Very common (10% or more): Persistent pruritus (up to 74%), persistent burning/stinging (up to 71%), erythema (up to 60%), scaling (up to 60%), pruritus (up to 60%), dryness (up to 48%), pruritus immediately after administration (up to 30%), skin stinging or burning (up to 22%)
- Common (1% to 10%): Skin irritation, sunburn
- Uncommon (0.1% to 1%): Contact dermatitis/eczema, dermatitis, skin discomfort/pain, skin exfoliation, acne/acne flares, skin swelling
- Postmarketing reports: Allergic dermatitis/allergic contact dermatitis, rash, eczema, skin discoloration[Ref]
Pruritus, erythema, scaling, dryness, irritation, sunburn, and acne flares usually occurred during the first month of therapy and decreased thereafter. These side effects were reversible when treatment was discontinued.
Skin exfoliation was associated with skin exposed to mechanical abrasion (e.g., waxing).[Ref]
Local
- Very common (10% or more): Burning (up to 60%); burning immediately after application (up to 30%)
- Frequency not reported: Burning/stinging[Ref]
Burning and stinging usually occurred during the first month of therapy and decreased thereafter. These side effects were reversible when treatment was discontinued.[Ref]
Respiratory
Genitourinary
- Common (1% to 10%): Dysmenorrhea[Ref]
Ocular
- Uncommon (0.1% to 1%): Eyelid irritation, eyelid erythema, eyelid pruritus, eyelid swelling/edema
- Postmarketing reports: Conjunctivitis[Ref]
Gastrointestinal
- Uncommon (0.1% to 1%): Tooth anomaly, tooth disorder[Ref]
Hypersensitivity
- Rare (0.01% to 0.1%): Allergic reaction
- Postmarketing reports: Allergic contact dermatitis/allergic dermatitis[Ref]
Other
- Rare (0.01% to 0.1%): Lack of drug effect
- Frequency not reported: Flu syndrome[Ref]
Nervous system
References
1. (2001) "Product Information. Differin (adapalene topical)." Galderma Laboratories Inc
2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
3. Cerner Multum, Inc. "Australian Product Information."
Frequently asked questions
More about Plixda (adapalene topical)
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: topical acne agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Plixda side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.